Pomerantz Law Firm Launches Investigation into Capricor Therapeutics for Potential Securities Fraud

Pomerantz Law Firm Investigates Capricor Therapeutics, Inc.



On June 22, 2025, Pomerantz LLP announced an investigation concerning Capricor Therapeutics, Inc. (NASDAQ: CAPR) and its officers regarding potential securities fraud or unlawful business practices. Investors who believe they may have been affected by this activity are encouraged to reach out to Danielle Peyton at the firm. This investigation arises amidst troubling news regarding the company's clinical trial progress and its impact on stock performance.

On May 5, 2025, Capricor issued a press release stating that after a review meeting with the U.S. Food and Drug Administration (FDA), it was confirmed that the agency intends to hold an advisory committee meeting related to Capricor's Biologics License Application (BLA) for deramiocel, a promising investigational cell therapy for Duchenne muscular dystrophy (DMD) patients. Following this announcement, Capricor's stock price plummeted by $3.00, a staggering 29.13%, closing at $7.30 per share on May 6. Such a dramatic shift in stock value raises concerns among investors, triggers the Pomerantz investigation, and draws attention to Capricor's practices before and during the FDA review process.

The primary aim of Pomerantz's investigation is to ascertain whether Capricor and its executives have engaged in any fraudulent activities or deceitful conduct that may have adversely impacted shareholders. Known for its strong reputation in corporate, securities, and antitrust class action litigation, Pomerantz seeks to hold accountable those who jeopardize investor interests. Founded by the late Abraham L. Pomerantz, the firm has a long history of recovering significant damages on behalf of affected investors and victims of corporate misconduct.

To clarify the scope of the issue, it’s essential to understand the implications of Capricor's recent developments. The company's commitment to advancing treatments for DMD is significant, but the FDA's caution in their review process and the resultant stock fluctuations underline the risks connected with investing in biopharmaceutical companies. Investors must remain vigilant and informed about their investments, especially when turbulent news such as this arises.

Door-to-door inquiries and updates from Pomerantz will be crucial to understanding the case's development and any potential class action that may emerge as more data comes to light. Shareholders who have experienced losses due to the stock's decline and believe they have been misled regarding material information should consider participating in this investigation.

For more information and to register interest in any potential class action, individuals can directly contact Pomerantz LLP, reaffirming their commitment to protecting investor rights. Information on joining the class action is also available through various channels including the firm’s website.

As further developments happen, investors are advised to stay updated on Capricor's communications regarding their BLA and any decisions made by the FDA that could affect the company’s future and stock price. The Pomerantz investigation serves as a critical watchpoint in exploring and addressing any accountability due to the swift changes in Capricor’s stock performance and public disclosures.

In conclusion, while Capricor Therapeutics operates in an important space within biotech for treating serious medical conditions, the responsibilities that come with being a publicly traded company necessitate high standards of transparency and accountability. Pomerantz LLP’s investigation not only highlights these issues but also aims to ensure that investor interests are represented, and their rights protected in this complex landscape.

Topics Financial Services & Investing)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.